Arcutis Biotherapeutics, Inc. (ARQT)
Automate Your Wheel Strategy on ARQT
With Tiblio's Option Bot, you can configure your own wheel strategy including ARQT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARQT
- Rev/Share 2.4912
- Book/Share 1.2386
- PB 21.2418
- Debt/Equity 0.7198
- CurrentRatio 3.5003
- ROIC -0.1405
- MktCap 3222764520.0
- FreeCF/Share -0.2997
- PFCF -84.2685
- PE -75.7549
- Debt/Assets 0.3067
- DivYield 0
- ROE -0.2969
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ARQT | Goldman | -- | Neutral | -- | $18 | July 25, 2025 |
| Initiation | ARQT | H.C. Wainwright | -- | Buy | -- | $19 | Dec. 30, 2024 |
| Initiation | ARQT | Jefferies | -- | Buy | -- | $15 | Aug. 28, 2024 |
News
Professional Golfer Max Homa Joins Arcutis' Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
Published: February 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms ZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas 10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalp WESTLAKE VILLAGE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that …
Read More
Arcutis After The Double: Hypergrowth Peaks, Compounding Remains
Published: February 20, 2026 by: Seeking Alpha
Sentiment: Positive
Arcutis Biotherapeutics shifts to Hold after a 100% rally, as much of the initial de-risked growth thesis has played out. ZORYVE approvals and revenue growth have driven a fair rerating, but forward expectations now imply slower compounding and less favorable risk/reward. ARQT's long-term upside remains via steroid market conversion and pipeline optionality, yet near-term catalysts are limited and growth deceleration is expected.
Read More
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy?
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Neutral
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
5 Biotech Stocks to Watch for Potential Upside
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
Read More
What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now?
Published: December 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Arcutis Biotherapeutics: The Earnings Inflection Has Arrived
Published: December 08, 2025 by: Seeking Alpha
Sentiment: Positive
Arcutis Biotherapeutics has transitioned to profitability, driven by Zoryve's strong sales growth and market acceptance. Management projects Zoryve peak sales of $2.6B–$3.5B, far above Wall Street's $1.69B estimate, supporting a bullish outlook. ARQT's Q3 net income reached $7.4M, with cash flow break-even now expected in Q4, de-risking the investment case.
Read More
Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock?
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to ARQT stock based on the movements in the options market lately.
Read More
Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Read More
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 26.5% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Arcutis Biotherapeutics (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Arcutis' Q3 Earnings: Increased Foam Share, Better GTN, And Clear 2026 Guide Made Share Rally
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Positive
Arcutis Biotherapeutics delivered strong Q3 results, driven by Zoryve foam's rapid adoption and a shift toward more patent-protected revenue. ARQT achieved earlier-than-expected profitability, established 2026 sales guidance of $455–$470M, and continues expanding Zoryve's label for broader indications. My DCF remodel values ARQT near $25/share, with a reasonable trading range of $15–$39, reflecting ambitious growth and margin assumptions.
Read More
Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade)
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Positive
Arcutis Biotherapeutics, Inc. surges after Q3 earnings, driven by strong Zoryve sales and outperformance versus Wall Street expectations. ARQT reported $99.2M in Q3 revenue (up 122% YoY), achieved profitability, and projects 2026 revenues of $455M-$470M with cash flow breakeven. Zoryve's expanding indications, large addressable market, and robust prescription growth support a bullish long-term outlook despite competition and reliance on a single product.
Read More
Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a year ago.
Read More
Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue?
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Read More
Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin types New data show improved quality of life and decreased impact on families for investigational ZORYVE cream 0.05% in children aged 2–5 years with atopic dermatitis Data demonstrate both ZORYVE cream 0.3% and ZORYVE foam 0.3% improved signs and symptoms of plaque psoriasis in individuals with facial and/or genital involvement WESTLAKE VILLAGE, Calif. and PARIS, Sept.
Read More
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Todd Watanabe - President, CEO & Director Latha Vairavan - Chief Financial Officer Conference Call Participants Jason Jun Presentation Jason Jun Great. Well, thanks, everyone, for joining the fireside session today with the Arcutis team.
Read More
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
Published: September 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topical steroids and vitamin-D analogs ZORYVE cream is uniquely formulated to be effective, safe, and well tolerated for all areas of the body, including sensitive areas such as intertriginous skin, where plaque psoriasis often presents in children WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental …
Read More
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.
Read More
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.
Read More
Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Positive
Upgrading Arcutis Biotherapeutics, Inc. from Hold to Buy due to Zoryve's strong regulatory and commercial momentum, with revenue and prescription growth exceeding expectations. Zoryve's expanding label, superior safety profile, and new foam formulation position it as a potential new standard of care in plaque psoriasis and atopic dermatitis. ARQ-255's upcoming Phase Ib results could unlock a first-in-class topical treatment for alopecia areata, adding long-term pipeline value.
Read More
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis' common stock to nine newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read More
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or minimal itch with ZORYVE cream 0.15% or ZORYVE cream 0.05% New data demonstrate that for children ages 2 to 5 who achieved disease clearance and switched to proactive twice-weekly application of investigational ZORYVE cream 0.05%, the median duration of disease control was 238 days Consistent efficacy, safety, and tolerability profile observed with ZORYVE cream WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a …
Read More
Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside
Published: June 05, 2025 by: Seeking Alpha
Sentiment: Positive
Arcutis Biotherapeutics has de-risked significantly post-2023, with approvals, revenue growth and a clear path to cash flow breakeven by 2026. Recent financials show a temporary and insignificant revenue dip and rising costs, but cash reserves and market expansion support near term stability. Pipeline progress and strategic partnerships, especially with Kowa, could multiply ARQT's market reach and addressable patient base.
Read More
About Arcutis Biotherapeutics, Inc. (ARQT)
- IPO Date 2020-01-31
- Website https://www.arcutis.com
- Industry Biotechnology
- CEO Todd Franklin Watanabe
- Employees 342